News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genmab A/S (GEN.CO) Reaches Fourth Milestone in Lundbeck Inc. (LUN.CO) Collaboration


12/6/2013 9:16:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Copenhagen, Denmark; December 6, 2013 – Genmab A/S (OMX: GEN) announced today it had reached an in vivo pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1.5 million payment (approximately DKK 11 million). Under the collaboration with Lundbeck, Genmab creates novel human antibodies to three central nervous system (CNS) targets identified by Lundbeck and Lundbeck has access to Genmab’s antibody creation and development capabilities.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES